Allogene Therapeutics (ALLO) Expected to Release Earnings on Thursday

Key Points

• Allogene Therapeutics is expected to report Q3 2026 results after market close on November 5, with analysts forecasting a loss of $0.1466 per share and no revenue.
• The company’s previous quarter beat estimates, reporting a $0.13-per-share loss versus expectations of $0.17 and revenue of $4.64 million. Analysts project full-year and next-year losses of $0.58 and $0.60 per share, respectively.
• Wall Street maintains a generally positive view, with a “Moderate Buy” consensus and an average price target of $8.30 versus the stock’s recent $1.30 price. Allogene is developing off-the-shelf CAR T-cell therapies for cancer.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.1466) per share and revenue of $0.00 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.17) by $0.04. The company had revenue of $4.64 million during the quarter, compared to analyst estimates of $0.00 million. On average, analysts expect Allogene Therapeutics to post ($0.58) EPS for the current fiscal year and ($0.60) EPS for the next fiscal year.

Allogene Therapeutics Stock Up 5.7%

NASDAQ:ALLO opened at $1.30 on Thursday. Allogene Therapeutics has a 12-month low of $1.04 and a 12-month high of $4.46. The firm has a market capitalization of $449.14 million, a P/E ratio of -1.94 and a beta of 0.56. The stock's fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.98.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ALLO shares. Weiss Ratings upgraded Allogene Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, October 21st. Citizens Jmp restated a "market outperform" rating and set a $6.00 target price on shares of Allogene Therapeutics in a report on Monday, August 17th. Finally, William Blair upgraded Allogene Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Allogene Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $8.30.

Insider Transactions at Allogene Therapeutics

In related news, CFO Geoffrey M. Parker sold 36,342 shares of Allogene Therapeutics stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $1.34, for a total value of $48,698.28. Following the sale, the chief financial officer owned 1,045,877 shares of the company's stock, valued at approximately $1,401,475.18. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Earl Douglas sold 29,697 shares of the business's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $2.12, for a total value of $62,957.64. Following the transaction, the senior vice president directly owned 488,267 shares in the company, valued at $1,035,126.04. This trade represents a 5.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.20% of the stock is currently owned by corporate insiders.

About Allogene Therapeutics

Allogene Therapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” CAR T cell therapies for cancer. Unlike conventional autologous CAR T treatments, which are manufactured from an individual patient's own cells, Allogene's approach uses healthy donor cells that can potentially be produced in advance and administered more quickly.

The company's investigational pipeline has included cemacabtagene ansegedleucel (cema-cel, formerly ALLO-501A) for certain patients with large B-cell lymphoma, as well as other allogeneic CAR T candidates being studied in blood cancers such as multiple myeloma and in solid tumors, including renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.